. 2019 Dec 23;59(5):531–544. doi: 10.1007/s40262-019-00855-0

Table 6.

Bioavailability of the upadacitinib extended-release formulation compared to the immediate-release formulation based on non-compartmental analyses using data from phase I studies

Pharmacokinetic parameter	Central value		Ratio of central values
	Central value		Point estimate	90% CI
	ER	IR	Point estimate	90% CI
Dose-normalized AUC_t	16.11	21.73	0.742	0.704–0.781
Dose-normalized AUC_∞	16.70	21.99	0.759	0.722–0.798

AUC_t area under the plasma concentration–time curve from time zero to time t, AUC_∞ area under the plasma concentration–time curve from time zero to infinity, CI confidence interval, ER extended-release, IR immediate-release